Navigation Links
United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
Date:5/1/2008

Annual Meeting of Shareholders to be Reconvened on May 29, 2008

SILVER SPRING, Md., May 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) (the Company) held its annual meeting of shareholders (the Annual Meeting) on April 29, 2008. The Company's shareholders voted to approve the election of Raymond Dwek, Roger Jeffs and Christopher Patusky as Class III directors with terms expiring in 2011. The Company's shareholders also voted to approve the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2008.

Following these votes, the Annual Meeting was adjourned and will be reconvened on May 29, 2008 to consider one remaining item of business: the adoption of the 2008 United Therapeutics Corporation Equity Incentive Plan (the 2008 Plan). The meeting was adjourned in order to allow shareholders time to consider a proposed amendment to the 2008 Plan (as so amended and restated, the Amended 2008 Plan).

The amendments reflected in the Amended 2008 Plan as compared with the original plan are summarized as follows:

Amendments Proposed Under the Amended Under the Original

2008 Plan 2008 Plan

Shares of common stock reserved

for grants 1,500,000 7,000,000

Final date for granting awards December 31, 2011 10 years after

shareholder approval

The ability to buy back awards Requires Allowed

or exchange them for other shareholder

consideration approval

The ability to lower the Requires Allowed

exercise price of any stock shareholder

option (other than in connection approval

with a change in our

capitalization)

Vesting of restricted stock - At least three Vesting period is

non performance based grants years vesting period discretionary

Vesting of restricted stock - At least one Vesting period is

performance based grants year vesting period discretionary

The Amended Plan request represents 3.57% of the Company's fully diluted voting shares.

The decision to adjourn the Annual Meeting and consider the Amended 2008 Plan at the reconvened Annual Meeting was made after the Company reported that a preliminary tally of the votes for the 2008 Plan indicated that the plan as originally proposed would not receive sufficient votes to be approved.

The reconvened Annual Meeting will be held at the Company's headquarters, 1110 Spring Street, Silver Spring, Maryland 20910, at 9:00 a.m. Eastern Time for the following purposes:

1. Approval of the Amended 2008 Plan; and

2. To consider and act upon such other business as may properly come

before the reconvened Annual Meeting.

Only holders of record of the Company's common stock at the close of business on March 7, 2008, the original record date, remain entitled to vote at the reconvened Annual Meeting.

The Company also announces that it filed with the Securities and Exchange Commission (SEC) today an amendment to its Proxy Statement filed with the SEC on March 7, 2008. The Company will mail the amendment and related information and proxy card to its shareholders of record as of March 7, 2008, on or about May 2, 2008. Shareholders are urged to read the amendment and other relevant documents because they relate to the approval of the Amended 2008 Plan.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
3. United BioSource Acquires Leading Publication Planning Software and Services Company
4. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
5. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
7. Moleac Launches NeuroAid10(TM) in the United States
8. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
9. United BioSource Expands Regulatory Affairs Capabilities
10. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
11. United States Patent Office Grants CryoCors Request for Patent Interference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... and HILDEN, Germany , March 29, 2017 ... PRIME STANDARD: QIA) today announced the U.S. launch of its ... which was cleared by the U.S. Food and Drug Administration as a qualitative ... genomic DNA extracted from EDTA whole blood.* ... The ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ® ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... that Nerium International Mexico has been approved as an active member of the ... satisfaction and protection among distributers and consumers in relationship marketing. This professional organization ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... for cell-based assays, disperses a quarterly travel award to noteworthy scientists who will ... company announced that its new round of awards are being given to two ...
(Date:3/29/2017)... 2017 /PRNewswire/ - The University of Missouri Research Reactor ... of Sterigenics International, and General Atomics (GA), announce that ... the U.S. Nuclear Regulatory Commission (NRC). This marks a ... (Mo-99). Once operational, production from this facility will be ... Mo-99, which currently must be imported from outside ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
Breaking Biology News(10 mins):